Citations

Clear

4510 citation(s) found for "Scott, C".

Incorporating Pelvic Floor Physical Therapy in the Treatment of Obstructed Defecation Syndrome and Posterior Compartment Pelvic Organ and Rectal Prolapse: Proceedings of the Consensus Meeting of the Pelvic Floor Consortium of the American Society of Colon
Traugott, Amber , Barten, Julia, Bordeianou, Liliana , Carboni, Cristiane , Carver, Donna, Cucchiara, Meghan Markowski, Gallo, Gaetano, Grimes, Cara L. , Knoepp, Leise R., McClure, Amanda M., Mellgren, Anders, Olson, Craig , Paquette, Ian M., Perry, William R., Snyder, Allison D., Spivak, A, Wells, Katerina O. K., Weinstein, Milena M. , Gurland, Brooke , Perry, William , Traugott, Amber L , Perry, William R , Gallo, Gaetano , Spivak, Anna R.

Mayo Clinic

Diseases of the Colon & Rectum | February 12, 2026 | Volume: 69 | Issue: 3 | Pages: 346-359

10.1097/dcr.0000000000003993 | PMID 41677229 Get It

BACKGROUND: Obstructed defecation syndrome and posterior compartment (rectal) prolapse significantly impact patients’ quality of life. Pelvic floor physical therapy is a critical part of multidisciplinary management for these conditions, yet there is little guidance or standardization to guide providers’ referral practices, diagnostic approaches, or treatment. OBJECTIVE: To develop multidisciplinary consensus-based recommendations for incorporating pelvic floor physical therapy into the treatment of obstructed defecation syndrome and posterior compartment prolapse. DATA SOURCES: MEDLINE, PubMed, Embase, and the Cochrane Database of Systematic Reviews were searched for English-language studies on pelvic floor physical therapy, obstructed defecation, diagnostic criteria, imaging, and pelvic organ prolapse. STUDY SELECTION: Studies identified in the literature search were reviewed by multidisciplinary expert subgroups, who formulated draft statements based on the available evidence. INTERVENTION: Consensus meetings were conducted and included experts from colorectal surgery, urogynecology, physical therapy, gastroenterology, radiology, and urology. Statements were evaluated via structured discussions and voting processes. Those reaching more than 70% consensus were adopted for inclusion. Statements underwent final review and editing by the leadership of the American Society of Colon and Rectal Surgeons and the International Urogynecological Association. MAIN OUTCOME MEASURES: Consensus statements addressed referral criteria, diagnostic evaluations, therapy protocols, timing, coordination with surgery, and management of anatomical abnormalities. RESULTS: Fifteen statements reached consensus. Key recommendations included prompt referral to pelvic floor physical therapy for patients without contraindications, individualized therapy based on appropriate diagnostic evaluation and patient goals, timing of pelvic floor physical therapy relative to surgery, and trauma-informed patient care. LIMITATIONS: Recommendations primarily reflect expert consensus due to limited high-quality evidence. Variability in practitioner expertise and geographic access to trained therapists are barriers to consistent implementation. CONCLUSIONS: These recommendations provide structured guidance for integrating pelvic floor physical therapy into the management of obstructed defecation syndrome and rectal prolapse. Additional research and standardized training are essential to optimize patient outcomes.
Impact of a web‐based breast cancer surgery decision aid on knowledge and perceptions of feeling informed in clinics that care for socioeconomically disadvantaged patients: An Alliance Clinical Trial (A231701CD)
Schumacher, Jessica R. , Hanlon, Bret M., Zahrieh, David , Tucholka, Jennifer L. , McKinney, Grace, Tan, Angelina D., Breuer, Catherine R. , Bailey, Lisa, Higham, Anna M. , Wecsler, Julie S. , Arnold, Alicia H, Froix, Anthony J. , Dull, Scott, Abbott, Andrea M., Fine, Stephanie , McGuire, Kandace P. , Seydel, Anna S. , McNamara, Patricia, Chow, Selina , Neuman, Heather B. , Hanlon, Bret M. , Hanlon, Bret M , Arnold, Alicia , Abbott, Andrea M , Neuman, Heather B , Rathouz, Paul J. , McKinney, Grace, Bailey, Lisa, Abbott, Andrea M.

Mayo Clinic

Cancer | February 11, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70314 | PMID 41669989 Get It

Abstract Objective To test the effectiveness of a surgical web‐based decision aid (DA) in improving knowledge. Summary of Background Data DAs support decision making by providing information about the options. Methods A stepped wedge trial was conducted in 10 National Cancer Institute Community Oncology Research Program clinics (Alliance for Clinical Trials in Oncology). Clinics were randomized to time of transition from usual care (UC) to delivery of a web‐based DA. Patients with stage 0 through 3 breast cancer being considered for surgery were enrolled. Knowledge (primary outcome) was measured using the Breast Cancer Surgery Decision Quality Instrument and patients were asked, “How informed do you feel?” Intervention effects were tested with linear mixed‐effects models, accounting for surgeon and clinic‐level clustering, time, and enrollment after COVID. Additional models controlled for demographics. Results A total of 44% of DA arm patients reviewed the DA and 58% in UC arm reported reviewing “any information.” Being in the DA arm versus UC was not associated with knowledge. However, “review of information” was associated with higher knowledge. In addition, non‐White race and lower education were associated with lower knowledge. The DA arm was associated with higher perceptions of feeling informed (parameter estimate 1.36; 95% CI, 0.18–2.55; p = .02); this persisted even when controlling for review of information or demographics. Conclusion Improved knowledge was not demonstrate with a web‐based DA versus UC. Interestingly, the DA was associated with a higher likelihood of feeling informed. Future research will explore the discrepancy between patients feeling informed but having low knowledge, especially for disadvantaged patients. Trial Registration ClinicalTrials.gov Identifier: NCT0376600
A Decade of Impact: Outcomes and Opportunities From the College of American Pathologists Foundation Grants and Awards Program
Reese, Rebecca, Johnson, Curtiss, Rankenburg, Julia A., Wang, Tengfei, Ahmed, Aadil, Atiya, Samir , Reese, Rebecca

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2026 | Volume: 150 | Issue: 5 | Pages: 391-402

10.5858/arpa.2025-0461-oa | PMID 41461171 Get It

Context.— Pathology is essential to global health care, yet disparities remain in access to education and training. The College of American Pathologists (CAP) Foundation addresses these gaps through grants and awards that support trainees, early-career pathologists, and initiatives promoting equity worldwide. Since 2015, total funding has increased from $18,400 to $84,098, an astounding 357%. Objective.— To evaluate the CAP Foundation Grants and Awards Program during a 10-year period, assessing financial investment, award distribution, recipient characteristics, and impact. Design.— A mixed-methods retrospective study integrated (1) quantitative analysis of program data, (2) qualitative feedback from awardees, and (3) a quantitative award impact survey of past CAP Foundation awardees. Variables included demographics, award type, funding amounts, geographic distribution, and career stage. Surveys assessed professional development, mentorship, and long-term engagement with CAP. Results.— From 2015 to 2024, a total of 744 applicants submitted 760 applications, resulting in 355 awards across 14 categories. Applications increased more than 8-fold, peaking in 2023, with surges during the COVID-19 pandemic. Medical student applications grew from 1 in 2020 to 17 in 2024 (76% annual growth); 9 of 12 Medical Student Travel Award recipients (75%) entered pathology residency. Geographic disparities were noted, with smaller residency programs showing higher per capita application rates. Among 174 survey respondents, 129 (74%) reported networking benefits, 127 (73%) learning benefits, and 99 (57%) mentorship benefits, though only 49 (28%) sustained long-term mentoring relationships. Conclusions.— The CAP Foundation’s awards program has expanded access, supported career development, and fostered future pathologists. Strengthening long-term mentorship and bridging education-to-practice gaps may further enhance its impact.
A Proteoform-Resolved Atlas of Human Cardiac Histones
Gao, Zhan, Clemmer, Isabella R., Chan, Hsin-Ju, Osei, Kwame, Weir, Thomas S., Fischer, Matthew S. , Gearhart, Robert, Price, Scott J., Zhu, Y., Wu, Jingshing, Zhu, Wuqiang , Zhu, Wuqiang , Gao, Zhan , Chan, Hsin‐Ju , Osei, Kwame, Rogers, Holden T. , Gearhart, Robert L., Price, Scott J., Brasier, Allan R. , Ge, Ying Ping

Mayo Clinic

No container title available | February 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8811072/v1 | PMID 41727594 Get It

Abstract Histones variant composition and post-translational modifications (PTMs) of core and linker histones jointly orchestrate chromatin architecture and tissue-specific gene regulation. However, capturing the full complexity of the “histone code” in native human tissues remains challenging. Here we present a human cardiac histone proteoform atlas—comprising intact histone variants with combinatorial PTMs—enabled by a streamlined top‑down proteomics workflow. In a single one‑dimensional reversed‑phase liquid chromatography (LC)-mass spectrometry (MS) run, we achieve baseline separation of all four core histone families (H2A, H2B, H3, and H4) together with the linker histone H1 directly from human myocardium. Notably, this intact-protein analysis preserves the connectivity of co-occurring PTMs to individual histone molecules to reveal the combinatorial histone code, enabling proteoform‑level quantification of histone‑variant composition and PTM stoichiometry at the chromatographic scale. Targeted MS/MS directly resolves co-occurring PTM combinations and distinguishes highly homologous histone isoforms. Using this approach, we assemble the first comprehensive cardiac histone proteoform atlas and uncover previously unobserved histone proteoforms. More broadly, this top-down proteomics workflow provides a robust framework for proteoform-resolved analysis of histone variants and PTMs in complex biological systems.
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Jegede, Opeyemi A. , Wang, Victoria, Ansell, Stephen M., Kostakoglu, Lale, Steidl, Christian , Natkunam, Yasodha , Scott, David W., Ambinder, Richard F, David, Kevin A. , Advani, Ranjana H, Bartlett, Nancy L., Thomas, Sachdev , Cohen, Jonathon B. , Goyal, Gaurav, Mehta-Shah, Neha, Amengual, Jennifer E. , Forlenza, Christopher Jon, Cole, Peter D. , Duan, Fenghai , Kelly, Kara M, Advani, Ranjana H. , Scott, David W. , Kostakoglu, Lale , Diefenbach, Catherine S , Jagede, Opeyemi A. , Kostakoglu, Lale , Steidl, Christian , Natkunam, Yasodha , Scott, David W , Ambinder, Richard F , David, Kevin , Bartlett, Nancy L , Thomas, Sachdev P , Cohen, Jonathon B , Goyal, Guarav , Mehta-Shah, Neha , Amengual, Jennifer E , Cole, Peter D , Advani, Ranjana H , Diefenbach, Catherine , Wang, Victoria , Ansell, Stephen M. , Ambinder, Richard F. , Bartlett, Nancy L. , Robertson, Michael J. , Ibrahimi, Sami , Goyal, Gaurav , Mehta–Shah, Neha , Forlenza, Christopher J. , Kelly, Kara M , Kahl, Brad S.

Mayo Clinic

Blood | February 9, 2026 | Volume: 147 | Issue: 18 | Pages: 2041-2052

10.1182/blood.2025029546 | PMID 41662628 Get It

Abstract The phase 1/2 Intergroup study E4412 investigated checkpoint blockade with nivolumab (Nivo) and ipilimumab (Ipi) combined with the CD30 targeting antibody-drug conjugate brentuximab vedotin (BV) in relapsed/refractory classic Hodgkin lymphoma. A total of 147 patients aged ≥12 years were randomized between BV/Nivo and BV/Ipi/Nivo; 132 patients were included in the primary efficacy analysis. The complete response (CR) rate, was 64.7% (52.2, 75.9) for BV/Nivo and 70.3% (57.6, 81.1) for BV/Ipi/Nivo (1-sided P = .29). The median survival follow-up was 38.0 months (interquartile range, 32.6-48.1). Progression-free survival (PFS) did not significantly differ between the 2 arms (hazard ratio [HR], 0.78, confidence interval [CI], 0.39-1.57; 1-sided P = .24). Treatment-related grade 3+ toxicities in the adult cohort, excluding rash, were similar between both arms (38.5% BV/Nivo and 39.3% BV/Ipi/Nivo); there was a higher frequency of grade 3 rash with BV/Ipi/Nivo (24.6%) compared with BV/Nivo (9.2%). We compared PFS by stem cell transplantation (SCT) status in a planned before hoc comparison; 58 patients received SCT, and 36-month PFS (from SCT) was >90% for both arms. Sixty-six patients were progression free after the first scan and did not undergo SCT. The 36-month PFS was 73.0% (54.5, 85.0) for BV/Ipi/Nivo compared with 45.8% (26.3, 63.4) for BV/Nivo (HR, 0.45; CI, 0.19-1.08; 1-sided P = .03). The study did not meet its primary end point of superior CR rate for the triplet, but it supports the use of checkpoint antibody-drug conjugate induction prior to auto SCT, and there is an intriguing signal of disease control for patients wishing to defer or avoid SCT with the triplet of BV/Ipi/Nivo. This trial was registered at www.clinicaltrials.gov as NCT01896999.
Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Abu-Rustum, Nadeem R, Campos, Susana M. , Amarnath, Sudha R. , Barber, Emma L. , Bradley, Kristin, Brooks, Rebecca , Chon, Hye Sook, Crispens, Marta Ann, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Kendra, Kari , Mantia-Smaldone, Gina , Mariani, Andrea , Mutch, David, Nagel, Christa , Nekhlyudov, Larissa, Nwachukwu, Chika, Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Nwachukwu, Chika , Abu‐Rustum, Nadeem R. , Arend, Rebecca C. , Bradley, Kristin , Chino, Junzo , Crispens, Marta Ann , Gaillard, Stéphanie , Glaser, Gretchen , Landrum, Lisa M. , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 3 | Pages: 101-126

10.6004/jnccn.2026.0011 | PMID 41825134 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vaginal Cancer outline the recommended diagnostic workup, staging considerations, and treatment options for this rare malignancy. Because vaginal cancer is uncommon and shares many biologic and clinical characteristics with cervical cancer, several management recommendations, particularly systemic therapy, are extrapolated from evidence and practices established for cervical cancer. This guideline excerpt summarizes key components of management, including diagnostic evaluation and workup, principles of staging, pathology considerations, radiation therapy principles, and primary treatment recommendations for both early-stage and advanced disease. It also details approaches to manage relapses, including locoregional recurrence and distant metastases, and provides an in-depth overview of systemic therapy recommendations for vaginal cancer.
High NKAP expression predicts poor prognosis of breast cancer patients
Li, Yonghao , Zheng, Shu , Sun, Chenyu, Lowe, Scott, Bentley, Rachel, Li, Yaru , King, Bethany, Chen, Shuya, Zhou, Qin, Zhang, Mei , Bentley, Rachel

Mayo Clinic

Medicine | February 6, 2026 | Volume: 105 | Issue: 6 | Pages: e47497

10.1097/md.0000000000047497 | PMID 41650063 Get It

NF-κB activating protein (NKAP) plays important roles in various cancers, including breast cancer. However, its expression and prognosis value in breast cancer remains uncertain. Gene expression profiling interactive analysis, Human protein atlas database, and University of Alabama at Birmingham Cancer data analysis portal database were used to predict the expression and prognostic value of NKAP in breast cancer. Immunohistochemistry, quantitative real time polymerase chain reaction (qRT-PCR) and western blot were performed to detect NKAP expression. The effects of NKAP on cell proliferation, migration and drug sensitivity were investigated in MDA-MB-231 and SK-BR-3 cells. NKAP protein expression differed in breast cancer tissues and paraneoplastic tissues based on the cancer genome atlas data. The high NKAP expression was significantly correlated with a poor prognosis in breast cancer patients. The results of immunohistochemistry, western blot assay, and qRT-PCR proved that NKAP was highly expressed in breast cancer tissues compared with paraneoplastic tissues. In addition, qRT-PCR results showed that high expression of NKAP was significantly correlated with the larger tumor size and higher TNM stage. Moreover, knockdown of NKAP significantly inhibited the proliferation, migration, and enhanced drug sensitivity of MDA-MB-231 and SK-BR-3 cells. NKAP is highly expressed in breast cancer tissues, and its high expression is closely associated with poor prognosis. NKAP also promotes proliferation, migration, and inhibits drug sensitivity of breast cancer cells.
The Sport Publication Observational Research Tool (SPORT): An Objective Tool to Score the Methodological Quality of Observational Clinical Sports Medicine Research
Kuhn, Andrew W. , Inclan, Paul M. , Haider, Ameer A. , Christy, Michele, Dunn, Warren, Alberton, Laura A. , Allen, Christina, Anderson, Kyle, Andrews, James, Azar, Fred, Baer, Geoffrey S. , Banffy, Michael B. , Bedi, Asheesh , Brockmeier, Stephen F., Brophy, Robert H. , Bush‐Joseph, Charles A., Carey, James R. , Carter, Thomas, Cohen, Steven, Farrow, Lutul D. , Flanigan, D. Preston, Franklin, Corinna C. , Hame, Sharon L. , Ioannis, Terzidis, Joseph, Sheeba, Kenter, Keith , Koh, Jason R., Krych, Aaron, LeClere, LT Lance, Levy, Bruce, McAllister, David, Morganti, Christina, Musahl, Volker , Nelson, Bradley , Noyes, Frank, Owens, COL Brett D., Pace, Lee, Paulos, Lonnie E., Rodeo, Scott, Safran, Marc, Savoie, Felix H. , Shelbourne, Donald K., Sherman, Seth L. , Singer, Ken, Smith, Matthew, Sonnery-Cottet, Bertrand, Spiker, Andrea M. , Stuart, Michael, Warren, Russell, Wittstein, Jocelyn R. , Wolcott, Michelle L., Wright, Rick, Matava, Matthew J. , Sherman, Seth L. , Kuhn, Andrew W , Dunn, Warren R., Brockmeier, Stephen F. , Brophy, Robert H. , Carey, James, Cohen, Steven B. , Flanigan, David, Krych, Aaron J. , LeClere, Lance E. , Lee, Cassandra Alda , Levy, Bruce, McAllister, David R. , Medvecky, Michael J. , Owens, Brett D. , Pace, J Lee , Redler, Lauren H. , Rodeo, Scott A. , Sonnery‐Cottet, Bertrand

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 6, 2026 | Volume: 14 | Issue: 2 | Pages: No page available

10.1177/23259671251380883 | PMID 41660291 Get It

Background: A critical component of conducting systematic reviews or meta-analyses is assessing the methodological quality and bias of included studies. Several methodological quality assessment tools have been developed; however, these tools may not be relevant to observational sports medicine research, which carries numerous unique nuances and biases. Purpose: To develop the Sport Publication Observational Research Tool (SPORT), which evaluates and scores the methodological quality of observational sports medicine research. Study Design: Consensus statement. Methods: SPORT was developed through a modified Delphi approach involving members from the Herodicus Society and The FORUM. All active members were invited to participate in the process aimed at building consensus on SPORT content and scoring. After finalizing SPORT, a power analysis led to the independent selection of 55 observational clinical sports medicine studies, which were scored twice by 4 reviewers of varying training levels. Interrater and intrarater reliability for SPORT was assessed using intraclass correlation coefficients (ICCs). The distribution and percentiles for total SPORT score across the 55 studies were calculated. SPORT was also compared with the methodological index for non-randomized studies (MINORS), a commonly utilized quality assessment tool. Results: A total of 51 members participated and achieved 100%, 100%, 98.0%, and 98.0% completion rates for rounds 1 through 4, respectively. The final SPORT included 19 subscores related to methodological quality and bias and achieved 94% consensus approval. Mean SPORT completion time was 6 minutes and 19 seconds per study, which varied significantly by reviewer training level. The subscore "peer review" demonstrated unacceptable reliability and was removed. The remaining 18 subscores exhibited ICC ranges of 0.599 to 0.955 for interrater reliability and 0.530 to 0.936 for intrarater reliability. Total SPORT score demonstrated excellent agreement, for interrater (ICC, 0.967) and intrarater reliability (ICC, 0.966). Median SPORT score across the 55 studies was 20.0 and skewed toward lower scores. There was a moderate significant correlation between SPORT and MINORS ( r [53] = 0.575; P < .001). Conclusion: An objective tool to assess the methodologic quality of observational sports medicine research (SPORT) was successfully developed through a modified Delphi approach with numerous content experts in the field. This tool may be useful in assessing the methodological quality of primary observational sports medicine studies included in systematic reviews and meta-analyses.
Quantitative SPECT/CT for diagnosis of transthyretin amyloid cardiomyopathy: a pathology-based study
Tersalvi, G, Carey, P, Garmany, A, Scott, C G, Homb, A C, Hoffman, A C, Zhang, J, Davies, D R, Askew, J W, Dispenzieri, A, Grogan, M, Chareonthaitawee, P, Johnson, G B, Bois, M C, Abouezzeddine, O F, Tersalvi, Gregorio , Carey, Patricia , Garmany, Armin , Scott, Christopher G. , Homb, Andrew, Davies, Daniel R. , Askew, J. Wells , Dispenzieri, Angela , Grogan, M, Chareonthaitawee, Panithaya , Johnson, Geoffrey B , Bois, Melanie C. , AbouEzzeddine, Omar F.

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.304 Get It

Abstract Background 99mTc-labelled cardiac scintigraphy enables noninvasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). Guidelines recommend using planar semiquantitative (heart to contralateral ratio, H/CL) and single photon emission computed tomography (SPECT) qualitative visual grading for diagnostic interpretation. However, planar imaging has inherent limitations, and visual grading is prone to interobserver variability, underscoring the need for standardized quantitative assessment. We developed a 3D volumetric quantitative score (3D Score) and assessed its diagnostic performance compared to myocardial tissue, the gold standard for ATTR-CM diagnosis. Methods At a single, tertiary referral center, we retrospectively identified consecutive patients from 06/2017 to 06/2024 who underwent 3-hour 99mTc-pyrophosphate or 99mTc-hydroxymethylene diphosphonate planar and SPECT/CT for suspected ATTR-CM and had archived myocardial tissue (biopsy or myectomy). On planar imaging, H/CL was calculated. On SPECT/CT, volumes of interest were drawn around the entire left ventricle (LV), avoiding calcifications, and within the right atrium (RA) blood pool. Mean uptake values were used to calculate the 3D Score (LVmean:RAmean), Fig 1A. Myocardial tissue was stained via sulfated Alcian blue and/or Congo red histochemistry. Once histologically confirmed, amyloid deposits were subtyped by liquid chromatography tandem mass spectrometry. The diagnostic performance of H/CL and 3D Score was assessed using receiver operating characteristic (ROC) curve analysis and predictive characteristics were defined. ROC areas under the curve (AUC) were compared using Delong test. Optimal cutoffs were determined using Youden’s J statistic. Baseline characteristics (demographics, echocardiogram, biomarkers) and H/CL were compared between patients above and below 3D Score cutoff. Results 239 patients were identified (median age 72 [65-78], 78% male, 46% ATTR positive). Median time between cardiac scintigraphy and myocardial tissue collection was 22 (6-65) days. Distribution of the 3D Score stratified by ATTR-CM status is illustrated in Fig 1B-C. The discriminative ability of the 3D Score was excellent (AUC 0.92) and superior to H/CL (0.87, p =0.006, Fig 1D-E). The optimal 3D Score cutoff for identifying ATTR-CM was ≥1.0 with sensitivity of 86%, specificity of 92%, positive predictive value (PPV) 90%, and negative predictive value (NPV) 89%. The optimal H/CL ratio cutoff for identifying ATTR-CM was ≥1.4 with sensitivity of 72%, specificity of 86%, PPV 81%, NPV 78%. Baseline characteristics of the overall cohort stratified by 3D Score are displayed in Table 1. Conclusions The 3D Score demonstrated excellent diagnostic performance for detecting ATTR-CM and was superior to current quantitative metrics. Future studies are needed to externally validate its performance across diverse patient cohorts and imaging centers and to investigate correlation with myocardial amyloid burden. Figure 1
Utility of polygenic risk scores for dilated cardiomyopathy in the general population
Figueiral, M, Jenkins, Gregory D. , Scott, C, Klee, E W, Rodeheffer, R J, Inojosa, J R Medina, Redfield, M M, Burnett, J C, Lopez-Jimenez, F, Sinagra, G, Merlo, M, Pereira, N L, Paldino, Alessia , Figueiral, Marta , Scott, Christopher G. , Rodeheffer, Richard J. , Medina‐Inojosa, José R. , López-Jiménez, Francisco , Sinagra, Gianfranco , Merlo, Marco , Pereira, Naveen L.

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.2658 Get It

Abstract Background Common genetic variation has been linked to an increased risk of developing dilated cardiomyopathy (DCM) in case-control studies. However, the phenotypic profile and biological mechanisms by which genetic background may predispose individuals to DCM and outcomes in the general population remain unclear. Aim The primary objectives of this study were twofold: (1) to validate a DCM polygenic score (PRS-1) based on a prior meta-analysis of case–control genetic association studies [Tadros R et al. Nat Genet (2021)]; and (2) To apply this PRS, along with two recently developed PRSs for DCM [PRS-2 from Zheng SL et al. Nat Genet (2024) and PRS-3 from Jurgens SJ et al. Nat Genet (2024)] to a general population that underwent comprehensive longitudinal phenotypic assessments and had long-term outcomes available. Methods While the PRS-1 was derived from only 13 SNPs, PRS-2 and PRS-3 were generated from 709,534 and 1,072,247 SNPs, respectively with significant overlap between them. These DCM-PRSs were applied to an unselected community-based cohort (n=1897) aged &gt;45 years, who underwent a physical examination, echocardiogram, and blood sample at baseline. Subsequent clinical outcomes were collected over a median 16 year follow-up (IQR: 15-17). Results No significant differences between the quartiles were present in terms of age, sex (48% male), and cardiovascular risk factors (CV-RF) (such as hypertension, diabetes, and coronary artery disease). However, linear regression models demonstrated a significant correlation between all DCM-PRSs and left ventricular (LV) parameters, including LV ejection fraction, LV end-systolic diameter, and LV end-diastolic diameter (Table). Multivariable regression analysis confirmed that these correlations were independent of age, sex, CV-RF, and population stratification (adjusted for the first 10 principal components [PCs]). During follow-up, 47 individuals developed DCM. A logistic regression analysis, using a 3:1 matched cohort of non-DCM vs. DCM individuals based on age and sex and adjusted for the same 10 PCs, found a significant correlation between DCM development and both PRS-1 [OR=2.27 (1.06–4.85), p=0.03] and PRS-3 [OR=2.63 (1.20–5.75), p=0.02], while PRS-2 did not show a significant association [OR=1.85 (0.84–4.06), p=0.12]. No association was found between the DCM-PRSs and heart failure (HF) biomarkers (aldosterone, natriuretic peptides, ST2, Galectin-3) or HF outcomes (all-cause mortality/HF hospitalization). Conclusion PRS-1 for DCM despite being derived from only 13 risk alleles, performs at least as well as the newer and more extensive PRSs, in its correlation with LV function, dimensions, and DCM development (except for PRS-2) in a general population. The absence of correlation between these DCM-PRSs and the renin-angiotensin-aldosterone system or natriuretic peptides suggests that genetic background influences LV traits through mechanisms independent of these biological pathways.